Company Overview
INmune Bio Inc. operates as a clinical-stage immunology company dedicated to the development of therapeutic drugs designed to reprogram the patient's innate immune system for the treatment of various diseases within the United States. The company functions within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on high-risk, high-reward research and development aimed at creating novel medical solutions. INmune Bio Inc. maintains a market capitalization of $29.78M and generates $50,000 in annual revenue based on trailing twelve-month figures, while employing a workforce of 13 individuals. These financial metrics indicate that the company is a small-cap entity with minimal current revenue generation, reflecting its status as a pre-revenue or early-stage biotechnology firm where the primary asset is its pipeline of product candidates intended for hematologic malignancies, solid tumors, and chronic inflammation rather than immediate cash flow.
Financial Health
The company reports a revenue of $50,000 for the trailing twelve months, alongside a net income of $-49,887,000 and an EBITDA metric that is not available. The substantial disparity between the nominal revenue of $50,000 and the net loss of $49.887 million reveals a cost structure heavily weighted toward research and development expenses and other operational costs that far exceed current sales. Free cash flow stands at $-19,256,876, indicating that the company is burning cash at a significant rate, which necessitates continuous access to external capital to sustain operations until product commercialization occurs. The gross margin is recorded at 100.0%, a figure typical for companies with no cost of goods sold yet, whereas the operating margin is -69,724.0% and the profit margin is 0.0%, highlighting the extreme leverage of fixed costs against negligible revenue. Total cash on hand is $27.73M, which exceeds total debt of $1.08M, suggesting a balance sheet that relies on equity financing rather than debt leverage. The debt-to-equity ratio is 4.26, a metric that, while high, reflects a capital structure dependent on shareholder equity given the lack of significant interest-bearing debt. Additionally, the current ratio is 4.17, indicating strong short-term liquidity relative to current liabilities, though this liquidity is primarily composed of cash reserves rather than operational earnings. Return on Equity is -155.8% and Return on Assets is -50.6%, metrics that reveal that management is currently utilizing the company's capital base to fund growth initiatives that have not yet generated positive returns or profitability.
Valuation Assessment
The trailing P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed at -1.43, a negative figure that implies the market expects the company to remain unprofitable in the near term. The price-to-book ratio is 1.17, indicating that the market values the company at a slight premium over its book value, suggesting that investors place value on the company's intellectual property and clinical pipeline beyond its tangible assets. The price-to-sales ratio is an exceptionally high 595.51, and the EV/EBITDA is not available; these alternative valuation metrics suggest that the company is being priced almost entirely on its potential future success rather than current financial performance or sales volume. The stock has reached a 52-week high of $11.64 and a 52-week low of $1.12, and without a specific current share price provided in the data, the valuation must be interpreted through these extreme volatility bounds which define the investor's risk exposure. The beta value is 0.85, meaning the stock's price volatility is slightly lower than the broader market, indicating a moderate correlation with overall market movements despite the inherent risks associated with the biotechnology sector.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available in the provided financial data, preventing a quantitative comparison of whether earnings are growing faster or slower than revenue. The company does not pay a dividend, evidenced by a dividend yield of not available and a payout ratio of 0.0%, which implies that the company reinvests all available resources and potential earnings back into research, development, and operational scaling rather than distributing income to shareholders. This strategy is consistent with clinical-stage biotechnology firms that prioritize funding their drug development programs to advance their candidates through clinical trials to hematologic malignancies, solid tumors, and chronic inflammation conditions. Consequently, the overall growth and income profile is characterized by a complete absence of current income generation and reliance on future product approvals to unlock value, rather than any current financial expansion metrics or dividend distributions.